Novo Nordisk shares surged 6.87% to $86.67 on Friday morning following the release of promising trial results for its new obesity treatment, amycretin. The company reported that the drug demonstrated significant weight-loss effects during a Phase 1b/2a clinical trial, sparking optimism about its potential in the competitive obesity treatment market. The trial evaluated amycretin’s safety, tolerability, and efficacy among 125 overweight and obese participants. Results showed that patients experienced up to 22% weight loss over 36 weeks.
Those receiving a 1.25 mg dose for 20 weeks lost an average of 9.7% of their weight, while participants on a 5 mg dose for 28 weeks saw a reduction of 16.2%. The highest dose group, receiving 20 mg over 36 weeks, achieved the most significant results, with a 22% weight loss. In contrast, individuals in the placebo group reported slight weight gains of 1.9% to 2.3%. Novo Nordisk noted that amycretin’s safety profile aligns with its widely-used semaglutide and Eli Lilly’s tirzepatide, both key players in the obesity treatment space.
The findings could position amycretin as a potential next-generation therapy for obesity management, reinforcing Novo Nordisk’s leadership in this rapidly growing sector. The company also highlighted earlier trials testing an oral version of amycretin, which showed comparable weight-loss outcomes, further bolstering the drug’s appeal. These results underline Novo Nordisk’s commitment to innovation in addressing obesity, a global health challenge with limited effective long-term treatment options.
Martin Lange, Novo Nordisk’s head of drug development, emphasized the significance of these findings, stating that they validate amycretin’s potential to become a transformative treatment in obesity care. Industry analysts view these results as a positive indicator for the drug’s future regulatory and commercial success. Novo Nordisk’s amycretin results come at a time of heightened competition in the obesity market, with Eli Lilly’s tirzepatide also delivering strong results in clinical trials.
Both companies are striving to capture a share of the lucrative obesity therapeutics market, which continues to grow due to increasing global rates of obesity and associated health conditions. The announcement further boosted investor confidence, with Novo Nordisk shares gaining momentum as the company solidifies its position as a leading player in the development of innovative weight-loss solutions. – By MENA Newswire News Desk.
